1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
4.1. Product Pipeline
4.2. Patent Analysis
5. BIOSIMILARS MARKET BY TYPE
5.1. Introduction
5.2. Monoclonal Antibodies
5.3. Erythropoietins (EPO)
5.4. Granulocyte-Colony Stimulating Factors (G-CSF)
5.5. Interferons
5.6. Hormone-based Biosimilars
5.7. Others
6. BIOSIMILARS MARKET BY DISEASE
6.1. Introduction
6.2. Infectious Disease
6.3. Oncology and Immunology
6.4. Respiratory
6.5. Genetic Disorders
6.6. Others
7. BIOSIMILARS MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. United Kingdom
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. India
7.6.4. South Korea
7.6.5. Taiwan
7.6.6. Thailand
7.6.7. Indosneisa
7.6.8. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Samsung Bioepis
9.2. Stada Arzneimittel AG
9.3. Sandoz International GmbH (Novartis)
9.4. Amgen Inc.
9.5. Apotex Inc.
9.6. BioCad
9.7. Dr. Reddy’s Laboratories Ltd.
9.8. Biocon
9.9. Boehringer Ingelheim International GmbH
9.10. Pfizer
9.11. BioFactura
10. APPENDIX
10.1. Currency
10.2. Assumptions
10.3. Base and Forecast Years Timeline
10.4. Key Benefits for the Stakeholders
10.5. Research Methodology
10.6. Abbreviations